Sign in
Taking peoplePhase 3

A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP

Key facts

Who runs it
Qilu Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
420 people, planned
Started
22 Jan 2026
Expected to end
Oct 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Meropenem and Pralurbactam
  • Ceftazidime-avibactam
Record updated
17 February 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • 1. Male or female participants ≥18 and ≤80 years of age; have a diagnosis of HAP/VAP; have systemic signs and respiratory signs or symptoms of HAP/VAP; New or worsening infiltrate on chest X-ray/CT obtained within 48 hours prior to screening; The estimated survival time is at lest 28 days

Who cannot take part

  • 1. Diagnosed or suspected CAP, Atypical pneumonias, Viral pneumonia or Chemical pneumonia; The total duration of antibiotic exposure for antibiotics whose administration begins in the 72 hours is longer than 24 hours; Acute Physiology and Chronic Health Evaluation (APACHE) II score >30; Allergic to any carbapenem, cephalosporin, penicillin, metronidazole disodium phosphate, other beta-lactam drugs or other beta-lactamase inhibitors and their auxiliary materials; Those who have a history of drug abuse or drug abuse within 6 months before screening; Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is to evaluate the efficacy and safety of Meropenem and Pralurbactam for Injection in Subjects with HABP/VABP. The primary objective is to demonstrate non-inferiority of Meropenem and Pralurbactam to Ceftazidime and Avibactam Sodium for Injection. This study is a randomized, double-blind, active-controlled study. The total duration of the study will be approximately 32 days including screening and follow-up.

The 2 groups in the trial

  • Meropenem and PralurbactamTreatment being tested
  • Ceftazidime-avibactamExisting treatment, for comparison

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blind, Active-Controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam for Injection Compared to Ceftazidime and Avibactam Sodium for Injection in Subjects With Hospital-acquired and Ventilator-associated Bacterial Pneumonia
Criteria questions
Built from NCT07327619, who can take part
Record updated
17 February 2026